Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 5/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 3/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | BRD2 | P25440 | 1/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25423134 | 0.85 | NTRK1 (0.43) | RXRATDP1NTRK1KDM4EMEN1 | |
| SCHEMBL4459616 | 0.84 | EPHX2 (0.44) | RXRATDP1NTRK1KDM4EALDH1A1 | |
| SCHEMBL20944793 | 0.84 | RXRA (0.45) | RXRATDP1BRD4 | |
| SCHEMBL20944828 | 0.83 | TDP1 (0.55) | RXRATDP1NTRK1KDM4EMEN1 | |
| SCHEMBL20944823 | 0.82 | ALDH1A1 (0.49) | RXRAKDM4EALDH1A1MAPT | |
| SCHEMBL4459657 | 0.82 | TDP1 (0.44) | RXRATDP1TACR1 | |
| SCHEMBL7239832 | 0.81 | SRD5A1 (0.48) | TDP1ALDH1A1MAPT | |
| SCHEMBL20944830 | 0.80 | TDP1 (0.62) | TDP1MEN1KMT2A | |
| SCHEMBL30631782 | 0.80 | TDP1 (0.62) | TDP1MEN1KMT2A | |
| SCHEMBL16312476 | 0.80 | TDP1 (0.60) | RXRATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3480187-B1 | METHOD FOR PREPARING INDENOISOQUINOLINE DERIVATIVES | UNIV NAT TAIWAN NORMAL (TW) | 2023-10-04 | — | — | EP | disclosed |
| US-10336704-B2 | Method for preparing indenoisoquinoline derivatives | NATIONAL TAIWAN NORMAL UNIVERSITY (TW) | 2019-07-02 | — | — | US | disclosed |
| US-10336704-B2 | Method for preparing indenoisoquinoline derivatives | NATIONAL TAIWAN NORMAL UNIVERSITY (TW) | 2019-07-02 | — | — | US | disclosed |
| EP-3480187-A1 | METHOD FOR PREPARING INDENOISOQUINOLINE DERIVATIVES | National Taiwan Normal University (TW) | 2019-05-08 | — | — | EP | disclosed |
| EP-3480187-A1 | METHOD FOR PREPARING INDENOISOQUINOLINE DERIVATIVES | National Taiwan Normal University (TW) | 2019-05-08 | — | — | EP | disclosed |
| US-20190127330-A1 | Method for Preparing Indenoisoquinoline Derivatives | NATIONAL TAIWAN NORMAL UNIVERSITY (TW) | 2019-05-02 | — | — | US | disclosed |
| US-20190127330-A1 | Method for Preparing Indenoisoquinoline Derivatives | NATIONAL TAIWAN NORMAL UNIVERSITY (TW) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336704-B2 | Method for preparing indenoisoquinoline derivatives | CYP1A2, RECQL, RDX | RXRA 1260/4885TDP1 3167/4885NTRK1 3014/4885 |
| US-20190127330-A1 | Method for Preparing Indenoisoquinoline Derivatives | CYP1A2, RECQL, RDX | RXRA 1260/4885TDP1 3167/4885NTRK1 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.